Synchronous Brain Metastases As a Poor Prognosis Factor in Clear Cell Renal Carcinoma: a Strong Argument for Systematic Brain Screening

Overview

Journal J Neurooncol

Publisher Springer

Date 2021 Apr 10

PMID 33837880

Citations 1

Authors

Valentine Ruste

Marie Pierre Sunyach

Ronan Tanguy

Emmanuel Jouanneau

Camille Schiffler

Melodie Carbonnaux

Guillaume Moriceau

Eve-Marie Neidhardt

Helen Boyle

Sophie Robin

Sylvie Negrier

Aude Flechon

Affiliations

Soon will be listed here.

Abstract

Purpose: Brain metastases (BM) usually represent a poor prognostic factor in solid tumors. About 10% of patients with renal cancer (RCC) will present BM. Local therapies such as stereotactic radiotherapy (SRT), whole brain radiotherapy (WBRT), and surgery are used to achieve brain control. We compared survival between patients with synchronous BM (SynBM group) and metachronous BM (MetaBM group).

Methods: It is a retrospective study of patients with clear cell renal cell carcinoma (ccRCC) and BM treated with TKI between 2005 and 2019 at the Centre Léon Bérard in Lyon. We collected prognostic factors: The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, the TNM stage, the histological subtypes and the Fuhrman grade. Overall survival (OS) was defined from diagnosis of metastatic ccRCC to death. Brain progression-free survival (B-PFS) was defined from focal brain therapy to brain progression or death.

Results: 99 patients were analyzed, 44 in the SynBM group and 55 in the MetaBM group. OS in the MetaBM group was 49.4 months versus 19.6 months in the SynBM group, p = 0.0002. The median time from diagnosis of metastasic disease to apparition of BM in the MetaBM group was 22.9 months (4.3; 125.7). SRT was used for 101 lesions (66.4%), WBRT for 25 patients (16.4%), surgery for 21 lesions (13.8%), surgery followed by radiation for 5 lesions (3.3%). B-PFS for all patients was 7 months (IC95% [5.0-10.5]).

Conclusions: Survival of patients with synchronous BM is inferior to that of patients with metachronous BM. Outcome is poor in both cases after diagnosis of BM. Brain screening should be encouraged at time of diagnosis of metastatis in ccRCC.

Citing Articles

Risk factors, prognostic factors, and nomograms for synchronous brain metastases of solid tumors: a population-based study.

Liu L, Che W, Xu B, Liu Y, Lyu J, Zhang Y Neurosurg Rev. 2024; 47(1):296.

PMID: 38922516 DOI: 10.1007/s10143-024-02519-5.

References

Cagney D, Martin A, Catalano P, Redig A, Lin N, Lee E . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11):1511-1521. PMC: 5737512. DOI: 10.1093/neuonc/nox077. View

Soffietti R, Kocher M, Abacioglu U, Villa S, Fauchon F, Baumert B . A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery:.... J Clin Oncol. 2012; 31(1):65-72. DOI: 10.1200/JCO.2011.41.0639. View

Muldoon L, Soussain C, Jahnke K, Johanson C, Siegal T, Smith Q . Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007; 25(16):2295-305. DOI: 10.1200/JCO.2006.09.9861. View

Lesueur P, Lequesne J, Barraux V, Kao W, Geffrelot J, Grellard J . Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer). Radiat Oncol. 2018; 13(1):138. PMC: 6064124. DOI: 10.1186/s13014-018-1083-1. View

Soffietti R, Abacioglu U, Baumert B, Combs S, Kinhult S, Kros J . Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017; 19(2):162-174. PMC: 5620494. DOI: 10.1093/neuonc/now241. View

Kumar A, Miller J, Hoffer S, Mansur D, Coffey M, Lo S . Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BED. J Neurooncol. 2018; 139(2):449-454. DOI: 10.1007/s11060-018-2885-6. View

Mahajan A, Ahmed S, McAleer M, Weinberg J, Li J, Brown P . Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017; 18(8):1040-1048. PMC: 5560102. DOI: 10.1016/S1470-2045(17)30414-X. View

Brown P, Jaeckle K, Ballman K, Farace E, Cerhan J, Anderson S . Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016; 316(4):401-409. PMC: 5313044. DOI: 10.1001/jama.2016.9839. View

Bianchi M, Sun M, Jeldres C, Shariat S, Trinh Q, Briganti A . Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2011; 23(4):973-80. DOI: 10.1093/annonc/mdr362. View

10.

Decker D, Decker V, Herskovic A, CUMMINGS G . Brain metastases in patients with renal cell carcinoma: prognosis and treatment. J Clin Oncol. 1984; 2(3):169-73. DOI: 10.1200/JCO.1984.2.3.169. View

11.

Bennani O, Derrey S, Langlois O, Castel H, Laquerriere A, Freger P . Brain metastasis from renal cell carcinoma. Neurochirurgie. 2014; 60(1-2):12-6. DOI: 10.1016/j.neuchi.2013.12.001. View

12.

Dudek A, Raza A, Chi M, Singhal M, Oberoi R, Mittapalli R . Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer. 2012; 11(2):155-60. PMC: 4467684. DOI: 10.1016/j.clgc.2012.11.001. View

13.

Choi S, Yoo S, You D, Jeong I, Song C, Hong B . Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma. Clin Genitourin Cancer. 2017; 15(6):717-723. DOI: 10.1016/j.clgc.2017.05.010. View

14.

Khan M, Zhao Z, Arooj S, Liao G . Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma. Front Oncol. 2020; 10:1246. PMC: 7390930. DOI: 10.3389/fonc.2020.01246. View

15.

Sperduto P, Mesko S, Li J, Cagney D, Aizer A, Lin N . Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020; 38(32):3773-3784. PMC: 7655019. DOI: 10.1200/JCO.20.01255. View

16.

Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J . Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014; 15(4):387-95. DOI: 10.1016/S1470-2045(14)70061-0. View

17.

Wolf A, Kvint S, Chachoua A, Pavlick A, Wilson M, Donahue B . Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery. J Neurosurg. 2017; 128(1):23-31. DOI: 10.3171/2016.10.JNS161036. View

18.

Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B . Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol. 2009; 21(5):1027-31. DOI: 10.1093/annonc/mdp411. View

19.

Verma J, Jonasch E, Allen P, Tannir N, Mahajan A . Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer. 2011; 117(21):4958-65. PMC: 4167837. DOI: 10.1002/cncr.26138. View

20.

Gore M, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason G . Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer. 2010; 117(3):501-9. DOI: 10.1002/cncr.25452. View